BIND Biosciences Inc.
This article was originally published in Start Up
BIND Biosciences generates nanoparticles with unique targeting agents that allow them to home in on cancerous cells with deadly precision. Because it's impossible to mathematically design the optimal particle, BIND scientists have created large combinatorial libraries of nanoparticles with different biophysical and chemical properties.
You may also be interested in...
The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.
Sept. 8 public meeting requests input on safety, efficacy points to consider for using nanotech in drugs, biologics.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Nanotechnology, a Balm for the Challenges of Drug Delivery," features profiles of BIND Biosciences, Liquidia Technologies, Nanolymf, Tempo Pharmaceuticals, and TransGenex Nanobiotech. Plus these Start-Ups Across Health Care: Breathe Technologies, Crospon, and InterMed Discovery.